GB9401090D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9401090D0
GB9401090D0 GB9401090A GB9401090A GB9401090D0 GB 9401090 D0 GB9401090 D0 GB 9401090D0 GB 9401090 A GB9401090 A GB 9401090A GB 9401090 A GB9401090 A GB 9401090A GB 9401090 D0 GB9401090 D0 GB 9401090D0
Authority
GB
United Kingdom
Prior art keywords
3alkyl
alkyl
represents hydrogen
ring
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9401090A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Glaxo Wellcome SA
Original Assignee
Laboratoires Glaxo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9401090(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Glaxo SA filed Critical Laboratoires Glaxo SA
Priority to GB9401090A priority Critical patent/GB9401090D0/en
Publication of GB9401090D0 publication Critical patent/GB9401090D0/en
Priority to HR950023A priority patent/HRP950023B1/xx
Priority to IS4252A priority patent/IS1888B/is
Priority to MYPI95000109A priority patent/MY114663A/en
Priority to TW084100415A priority patent/TW378210B/zh
Priority to HK98114572.0A priority patent/HK1013286B/en
Priority to PE1995259855A priority patent/PE49495A1/es
Priority to EE9600093A priority patent/EE03231B1/xx
Priority to CA002181377A priority patent/CA2181377C/en
Priority to ZA95424A priority patent/ZA95424B/xx
Priority to DE2003199006 priority patent/DE10399006I2/de
Priority to EP95907565A priority patent/EP0740668B1/en
Priority to US08/669,389 priority patent/US5859006A/en
Priority to AT95907565T priority patent/ATE169018T1/de
Priority to JP51933995A priority patent/JP3808095B2/ja
Priority to IL11238495A priority patent/IL112384A/en
Priority to PCT/EP1995/000183 priority patent/WO1995019978A1/en
Priority to CO95001858A priority patent/CO4340684A1/es
Priority to HU9601982A priority patent/HU222494B1/hu
Priority to ES95907565T priority patent/ES2122543T3/es
Priority to RU96117127A priority patent/RU2142463C1/ru
Priority to SK940-96A priority patent/SK280879B6/sk
Priority to EG4795A priority patent/EG25852A/xx
Priority to DE69503753T priority patent/DE69503753T2/de
Priority to NZ279199A priority patent/NZ279199A/en
Priority to DK95907565T priority patent/DK0740668T3/da
Priority to AU15748/95A priority patent/AU689205B2/en
Priority to SG1996007328A priority patent/SG49184A1/en
Priority to KR1019960703922A priority patent/KR100357411B1/ko
Priority to PL95315559A priority patent/PL179744B1/pl
Priority to MX9602904A priority patent/MX9602904A/es
Priority to RO96-01454A priority patent/RO117794B1/ro
Priority to CZ19962116A priority patent/CZ286566B6/cs
Priority to SI9530162T priority patent/SI0740668T1/xx
Priority to CN95192078A priority patent/CN1045777C/zh
Priority to BRPI9506559A priority patent/BR9506559C8/pt
Priority to APAP/P/1995/000712A priority patent/AP556A/en
Priority to MA23760A priority patent/MA23433A1/fr
Priority to UY23893A priority patent/UY23893A1/es
Priority to SV1995000002A priority patent/SV1995000002A/es
Priority to TNTNSN95004A priority patent/TNSN95004A1/fr
Priority to IN77DE1995 priority patent/IN183942B/en
Priority to SA95150475A priority patent/SA95150475B1/ar
Priority to LVP-96-228A priority patent/LV11690B/lv
Priority to OA60864A priority patent/OA10584A/en
Priority to BG100727A priority patent/BG62733B1/bg
Priority to NO963015A priority patent/NO306465B1/no
Priority to FI962927A priority patent/FI113176B/fi
Priority to AU73912/98A priority patent/AU707055B2/en
Priority to US09/133,078 priority patent/US6025494A/en
Priority to US09/154,051 priority patent/US6143746A/en
Priority to CN98122779A priority patent/CN1070492C/zh
Priority to US09/399,667 priority patent/US6127542A/en
Priority to US09/633,431 priority patent/US6369059B1/en
Priority to US10/068,114 priority patent/US6784179B2/en
Priority to NO2003002C priority patent/NO2003002I2/no
Priority to LU91017C priority patent/LU91017I2/fr
Priority to NL300124C priority patent/NL300124I2/nl
Priority to JP2004125881A priority patent/JP4347125B2/ja
Priority to JP2009006669A priority patent/JP2009102386A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB9401090A 1994-01-21 1994-01-21 Chemical compounds Pending GB9401090D0 (en)

Priority Applications (60)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds
HR950023A HRP950023B1 (en) 1994-01-21 1995-01-17 Tetracyclic derivatives, process of preparation and use
IS4252A IS1888B (is) 1994-01-21 1995-01-17 Pýrazínó[2',1':6,1]pýridó[3,4-b]indól-1,4-díón, aðferð við framleiðslu og notkun
MYPI95000109A MY114663A (en) 1994-01-21 1995-01-18 Tetracyclic derivatives,process of preparation and use.
TW084100415A TW378210B (en) 1994-01-21 1995-01-18 Tetracyclic derivatives; process of preparation and use
HK98114572.0A HK1013286B (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use
PE1995259855A PE49495A1 (es) 1994-01-21 1995-01-19 Derivado tetraciclico y proceso para su preparacion
EE9600093A EE03231B1 (et) 1994-01-21 1995-01-19 Tetratsüklilised derivaadid, nende valmistamismeetod ja kasutamine
CA002181377A CA2181377C (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use
ZA95424A ZA95424B (en) 1994-01-21 1995-01-19 Tetracyclic derivatives process of preparation and use
DE2003199006 DE10399006I2 (de) 1994-01-21 1995-01-19 Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
EP95907565A EP0740668B1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use
US08/669,389 US5859006A (en) 1994-01-21 1995-01-19 Tetracyclic derivatives; process of preparation and use
AT95907565T ATE169018T1 (de) 1994-01-21 1995-01-19 Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung
JP51933995A JP3808095B2 (ja) 1994-01-21 1995-01-19 四環式誘導体、製造方法および用途
IL11238495A IL112384A (en) 1994-01-21 1995-01-19 6-aryl-hexahydropyrazino [1',2':1,6] pyrido [3,4-b] indole-1, 4-dione derivatives their preparation and pharmaceutical compositions containing them
PCT/EP1995/000183 WO1995019978A1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use
CO95001858A CO4340684A1 (es) 1994-01-21 1995-01-19 Derivados de 2, 3, 6, 7 12, 12a-hexahidro-pirazin-[2´, 1´: 6´,1] pirido [3,4-b] indol- 1,4 diona y su proceso de preparacion
HU9601982A HU222494B1 (hu) 1994-01-21 1995-01-19 Pirazino-pirido-indol-származékok, előállításuk és gyógyszerkénti alkalmazásuk, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
ES95907565T ES2122543T3 (es) 1994-01-21 1995-01-19 Derivados tetraciclicos, proceso de preparacion y utilizacion.
RU96117127A RU2142463C1 (ru) 1994-01-21 1995-01-19 Тетрациклические производные, способ их получения (варианты), содержащий их фармацевтический состав, и их использование в терапии
SK940-96A SK280879B6 (sk) 1994-01-21 1995-01-19 Tetracyklické deriváty, spôsob ich výroby, ich použitie a farmaceutické prostriedky s ich obsahom
EG4795A EG25852A (en) 1994-01-21 1995-01-19 Teracyclic derivatives process of preparation
DE69503753T DE69503753T2 (de) 1994-01-21 1995-01-19 Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung
NZ279199A NZ279199A (en) 1994-01-21 1995-01-19 Pyrazino[2',1':6,1]pyrido[3,4-6]indole-1,4-dione derivatives and medicaments
DK95907565T DK0740668T3 (da) 1994-01-21 1995-01-19 Tetracykliske derivater, fremgangsmåde til deres fremstilling og deres anvendelse
AU15748/95A AU689205B2 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use
SG1996007328A SG49184A1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives process of preparing and use
KR1019960703922A KR100357411B1 (ko) 1994-01-21 1995-01-19 테트라시클릭유도체,제조방법및용도
PL95315559A PL179744B1 (pl) 1994-01-21 1995-01-19 Nowe zwiazki, pochodne tetracykliczne, srodek farmaceutyczny i sp osób wytwarzania pochodnych tetracyklicznych PL PL PL PL PL PL PL PL PL
MX9602904A MX9602904A (es) 1994-01-21 1995-01-19 Derivados tetraciclicos, procedimiento de preparacion y uso.
RO96-01454A RO117794B1 (ro) 1994-01-21 1995-01-19 Derivati indolici tetraciclici, procedeu de preparare si compozitie farmaceutica
CZ19962116A CZ286566B6 (cs) 1994-01-21 1995-01-19 Tetracyklické deriváty, způsoby jejich výroby, jejich použití a farmaceutické prostředky s jejich obsahem
SI9530162T SI0740668T1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use
CN95192078A CN1045777C (zh) 1994-01-21 1995-01-19 四环衍生物,制备方法和用途
BRPI9506559A BR9506559C8 (pt) 1994-01-21 1995-01-19 compostos de derivados tetracíclicos, isômero cis de derivados tetracíclicos, e, composição farmacêutica
APAP/P/1995/000712A AP556A (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use.
MA23760A MA23433A1 (fr) 1994-01-21 1995-01-20 Nouvelles compositions leurs procedes de preparation et leur emploi
UY23893A UY23893A1 (es) 1994-01-21 1995-01-20 Derivados tetraciclicos, procedimiento de preparación y uso
SV1995000002A SV1995000002A (es) 1994-01-21 1995-01-20 Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs
TNTNSN95004A TNSN95004A1 (fr) 1994-01-21 1995-01-20 Derives tetracycliques, procedes de preparation et emploi
IN77DE1995 IN183942B (en:Method) 1994-01-21 1995-01-20
SA95150475A SA95150475B1 (ar) 1994-01-21 1995-01-31 مشتقات رباعيه حلقية tetracyclic عملية لتحضيرها واستخدامها
LVP-96-228A LV11690B (en) 1994-01-21 1996-07-10 Tetracyclic derivatives, process of preparation and use
OA60864A OA10584A (en) 1994-01-21 1996-07-17 Tetracyclic derivatives process of preparation anduse
BG100727A BG62733B1 (bg) 1994-01-21 1996-07-18 Тетрациклени производни, метод за получаване и приложение
NO963015A NO306465B1 (no) 1994-01-21 1996-07-19 Tetracykliske derivater,cis isomer, anvendelse derav samt farmasöytisk blanding
FI962927A FI113176B (fi) 1994-01-21 1996-07-19 Pyratsino[2',1':6,1]pyrido[3,4-b]indoli-1,4-dionijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö
AU73912/98A AU707055B2 (en) 1994-01-21 1998-06-26 Tetracyclic derivatives, process of preparation and use
US09/133,078 US6025494A (en) 1994-01-21 1998-08-12 Tetracyclic derivatives, process of preparation and use
US09/154,051 US6143746A (en) 1994-01-21 1998-09-16 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
CN98122779A CN1070492C (zh) 1994-01-21 1998-12-01 四环衍生物,制备方法和用途
US09/399,667 US6127542A (en) 1994-01-21 1999-09-21 Tetracyclic derivatives, process of preparation and use
US09/633,431 US6369059B1 (en) 1994-01-21 2000-08-07 Tetracyclic derivatives, process of preparation and use
US10/068,114 US6784179B2 (en) 1994-01-21 2002-02-05 Tetracyclic derivatives, process of preparation and use
NO2003002C NO2003002I2 (no) 1994-01-21 2003-01-22 Tadalafil
LU91017C LU91017I2 (fr) 1994-01-21 2003-03-26 Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci
NL300124C NL300124I2 (nl) 1994-01-21 2003-04-23 Tetracyclische derivaten, werkwijze voor het bereiden daarvan, en hun toepassing.
JP2004125881A JP4347125B2 (ja) 1994-01-21 2004-04-21 四環式誘導体の中間体
JP2009006669A JP2009102386A (ja) 1994-01-21 2009-01-15 四環式誘導体の中間体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9401090D0 true GB9401090D0 (en) 1994-03-16

Family

ID=10749089

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9401090A Pending GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds

Country Status (48)

Country Link
US (5) US5859006A (en:Method)
EP (1) EP0740668B1 (en:Method)
JP (3) JP3808095B2 (en:Method)
KR (1) KR100357411B1 (en:Method)
CN (2) CN1045777C (en:Method)
AP (1) AP556A (en:Method)
AT (1) ATE169018T1 (en:Method)
AU (2) AU689205B2 (en:Method)
BG (1) BG62733B1 (en:Method)
BR (1) BR9506559C8 (en:Method)
CA (1) CA2181377C (en:Method)
CO (1) CO4340684A1 (en:Method)
CZ (1) CZ286566B6 (en:Method)
DE (2) DE69503753T2 (en:Method)
DK (1) DK0740668T3 (en:Method)
EE (1) EE03231B1 (en:Method)
EG (1) EG25852A (en:Method)
ES (1) ES2122543T3 (en:Method)
FI (1) FI113176B (en:Method)
GB (1) GB9401090D0 (en:Method)
HR (1) HRP950023B1 (en:Method)
HU (1) HU222494B1 (en:Method)
IL (1) IL112384A (en:Method)
IN (1) IN183942B (en:Method)
IS (1) IS1888B (en:Method)
LU (1) LU91017I2 (en:Method)
LV (1) LV11690B (en:Method)
MA (1) MA23433A1 (en:Method)
MX (1) MX9602904A (en:Method)
MY (1) MY114663A (en:Method)
NL (1) NL300124I2 (en:Method)
NO (2) NO306465B1 (en:Method)
NZ (1) NZ279199A (en:Method)
OA (1) OA10584A (en:Method)
PE (1) PE49495A1 (en:Method)
PL (1) PL179744B1 (en:Method)
RO (1) RO117794B1 (en:Method)
RU (1) RU2142463C1 (en:Method)
SA (1) SA95150475B1 (en:Method)
SG (1) SG49184A1 (en:Method)
SI (1) SI0740668T1 (en:Method)
SK (1) SK280879B6 (en:Method)
SV (1) SV1995000002A (en:Method)
TN (1) TNSN95004A1 (en:Method)
TW (1) TW378210B (en:Method)
UY (1) UY23893A1 (en:Method)
WO (1) WO1995019978A1 (en:Method)
ZA (1) ZA95424B (en:Method)

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
WO1997043287A1 (en) * 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
ES2213004T3 (es) 1999-03-24 2004-08-16 Harbor Branch Oceanographic Institution, Inc. Usos antiinflamatorios de manzaminas.
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
JP2003505509A (ja) 1999-08-03 2003-02-12 リリー アイコス リミテッド ライアビリティ カンパニー β−カルボリン製薬組成物
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
CA2387353A1 (en) 1999-10-11 2001-04-19 Charlotte Moira Norfor Allerton Pharmaceutically active compounds
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
CA2412594C (en) * 2000-06-23 2009-03-17 Lilly Icos Llc Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
CA2412596C (en) * 2000-06-23 2007-07-31 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
AU2001266575A1 (en) * 2000-06-26 2002-01-08 Lilly Icos Llc Chemical compounds
AU2001278480A1 (en) * 2000-07-24 2002-02-05 Bayer Crop Science Ag Biphenyl carboxamides
MXPA03000887A (es) * 2000-08-02 2004-04-05 Lilly Icos Llc Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6962918B2 (en) * 2000-10-02 2005-11-08 Lilly Icos Llc. Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
EP1211313A3 (en) * 2000-11-01 2003-04-23 Pfizer Limited Modulation of PDE11A activity
ATE337320T1 (de) * 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
ES2278956T3 (es) * 2001-04-25 2007-08-16 Lilly Icos Llc Derivados de carbolina como inhibidores de fosfodiesterasa 5 (pde5) para el tratamiento de enfermedades cardiovasculares y de la disfuncion erectil.
FR2824829B1 (fr) * 2001-05-16 2005-06-03 Macef Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
CA2445620C (en) * 2001-06-05 2008-07-08 Lilly Icos Llc Tetracyclic compounds as pde5-inhibitors
CA2445625C (en) 2001-06-05 2010-07-27 Lilly Icos Llc Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
WO2002098875A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
ATE335742T1 (de) * 2001-06-21 2006-09-15 Lilly Icos Llc Carbolinderivate als pdev inhibitoren
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2005509038A (ja) * 2001-11-09 2005-04-07 シェーリング　コーポレイション 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
DE60221425T2 (de) * 2001-11-14 2008-06-26 Ortho-Mcneil Pharmaceutical, Inc. Substituierte tetrazyklische pyrrolochinolonderivate als phosphodiesterase-inhibitoren
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN1655820A (zh) * 2002-05-23 2005-08-17 辉瑞大药厂 Pde5抑制剂与ace抑制剂的药物组合
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
ATE415402T1 (de) * 2002-07-31 2008-12-15 Lilly Icos Llc Modifizierte pictet-spengler-reaktion und damit hergestellte verbindungen
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PL377657A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
ES2326119T3 (es) 2003-04-29 2009-10-01 Pfizer Inc. 5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
EA012279B1 (ru) * 2003-05-22 2009-08-28 Никомед Гмбх Композиция, включающая ингибитор pde4 и ингибитор pde5
DK1644021T3 (da) * 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
AU2004299058A1 (en) * 2003-12-12 2005-06-30 Aventis Pharmaceutical, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005068464A2 (en) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US20060025463A1 (en) * 2004-03-22 2006-02-02 Michael Bristow Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
WO2005116030A1 (en) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd A process for the preparation of tadalafil
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
US8063214B2 (en) * 2004-10-28 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of tadalafil
EP1799216A2 (en) * 2004-11-02 2007-06-27 Teva Pharmaceutical Industries Ltd Tadalafil crystal forms and processes for preparing them
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
PL1829874T3 (pl) 2004-12-22 2014-07-31 Ono Pharmaceutical Co Tricykliczny związek i jego zastosowanie
MX2007009707A (es) * 2005-02-25 2007-09-12 Teva Pharma Proceso para sintetizar tadalafil.
JP2008520751A (ja) * 2005-02-25 2008-06-19 テバ ファーマシューティカル インダストリーズ リミティド 大粒子サイズを有するタダラフィル及びそれを調製する方法
JP2008527012A (ja) * 2005-02-25 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド タダラフィルの精製法
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
ES2278552T1 (es) * 2005-04-12 2007-08-16 Teva Pharmaceutical Industries Ltd Preparacion de intermediarios de tadalafil.
CN101163476A (zh) 2005-04-19 2008-04-16 尼科梅德有限责任公司 用于治疗肺动脉高血压的罗氟司特
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
PT1881985E (pt) 2005-05-12 2011-02-01 Pfizer Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
CA2616366A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
AU2006299833B2 (en) 2005-10-12 2012-04-12 Besins Healthcare Luxembourg Sarl Improved testosterone gel and method of use
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2004644A1 (en) * 2006-03-24 2008-12-24 Glenmark Pharmaceuticals Limited Process for the preparation of tadalafil
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
RU2009103660A (ru) * 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель
AU2007275634B2 (en) 2006-07-21 2011-01-20 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
EP2054041A2 (en) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007333115B2 (en) 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
KR101497509B1 (ko) 2007-02-12 2015-03-03 브릭스 파마슈티컬스 인코퍼레이티드 트라마돌의 부작용을 감소시키는 방법
PL2120570T3 (pl) * 2007-02-12 2012-10-31 Vyrix Pharmaceuticals Inc Leczenie współwystępującego przedwczesnego wytrysku i zaburzenia wzwodu prącia
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
MX2009011588A (es) * 2007-04-25 2009-11-05 Teva Pharma Formas de dosificacion solidas que comprenden tadalafil.
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
EP2170880B1 (en) 2007-06-29 2012-08-15 Ranbaxy Laboratories Limited A process for the preparation of intermediates of tetracyclic compounds
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (en) * 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Conversion of tryptophan into ß-carboline derivatives
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (en) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2400848A4 (en) 2009-02-26 2012-07-25 Thar Pharmaceuticals Inc CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2012051559A2 (en) 2010-10-15 2012-04-19 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107549A1 (en) 2011-02-10 2012-08-16 Interquim, S.A. PROCESS FOR OBTAINING COMPOUNDS DERIVED FROM TETRAHYDRO-ß-CARBOLINE
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2013109230A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2013109223A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2013109227A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
JP5941558B2 (ja) 2012-02-28 2016-06-29 株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
JP6120985B2 (ja) 2012-12-04 2017-04-26 アリビオ， インコーポレーテッド ホスホジエステラーゼタイプ５活性阻害剤を含む神経細胞のアポトーシス抑制用組成物
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
PE20151590A1 (es) 2013-02-21 2015-11-19 Adverio Pharma Gmbh Formas del metil {4,6-diamino-2- [1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
EP3022205B1 (en) 2013-07-17 2020-02-05 The Trustees of Columbia University in the City of New York Novel phosphodiesterase inhibitors and uses thereof
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
ES2784251T3 (es) 2014-06-30 2020-09-23 Montero Gida Sanayi Ve Ticaret As Formulaciones de disgregación por vía oral de tadalafilo
EP2962684A1 (en) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of tadalafil
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
EP3466951B1 (en) 2014-07-23 2022-01-19 KRKA, d.d., Novo mesto A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
WO2016206097A1 (zh) * 2015-06-26 2016-12-29 重庆文理学院 新的5型磷酸二酯酶抑制剂及其应用
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
WO2018112258A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
KR20210150495A (ko) 2019-04-10 2021-12-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
EP4001282A4 (en) 2019-07-15 2023-07-19 Biolab Sanus Farmacéutica Ltda STEREOISOMERS OF THE COMPOUND 3-(BENZO[D][1,3]DIOXOL-5-YL)-7-(1-HYDROXYPROPAN-3-YL)-1-(1H-INDOL-3-YL)-6,7- DIHYDRO-3H-OXAZOLE[3,4-A]PYRAZINE-5,8-DIONE AND USE THEREOF AS AN ANTI-TUMORROW AGENT AND PHOSPHODIESTERASE ENZYME INHIBITOR
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2024173675A1 (en) 2023-02-16 2024-08-22 University Of Rochester Improving glymphatic-lymphatic efflux
CN116715667A (zh) * 2023-06-20 2023-09-08 常州制药厂有限公司 一种他达拉非新晶型b及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Also Published As

Publication number Publication date
SI0740668T1 (en) 1999-02-28
UY23893A1 (es) 1995-07-11
FI962927A7 (fi) 1996-07-19
ATE169018T1 (de) 1998-08-15
LV11690A (lv) 1997-02-20
RU2142463C1 (ru) 1999-12-10
PE49495A1 (es) 1996-01-10
CN1143963A (zh) 1997-02-26
BG62733B1 (bg) 2000-06-30
NL300124I2 (nl) 2003-11-03
NO2003002I1 (no) 2003-01-22
HRP950023B1 (en) 2000-10-31
BR9506559A (pt) 1997-10-28
IN183942B (en:Method) 2000-05-20
US6784179B2 (en) 2004-08-31
FI113176B (fi) 2004-03-15
KR100357411B1 (ko) 2003-02-05
SK280879B6 (sk) 2000-08-14
NO306465B1 (no) 1999-11-08
ES2122543T3 (es) 1998-12-16
IS4252A (is) 1995-07-22
US5859006A (en) 1999-01-12
EE03231B1 (et) 1999-10-15
HU222494B1 (hu) 2003-07-28
DE69503753T2 (de) 1999-01-21
BG100727A (bg) 1997-02-28
CA2181377A1 (en) 1995-07-27
JP4347125B2 (ja) 2009-10-21
IL112384A0 (en) 1995-03-30
AU1574895A (en) 1995-08-08
IL112384A (en) 1998-08-16
SA95150475B1 (ar) 2005-07-31
TW378210B (en) 2000-01-01
HRP950023A2 (en) 1998-04-30
AP9500712A0 (en) 1995-01-31
CN1070492C (zh) 2001-09-05
CN1224720A (zh) 1999-08-04
MX9602904A (es) 1997-12-31
LV11690B (en) 1997-06-20
CZ286566B6 (cs) 2000-05-17
DK0740668T3 (da) 1999-05-03
US6025494A (en) 2000-02-15
PL315559A1 (en) 1996-11-12
DE69503753D1 (de) 1998-09-03
CO4340684A1 (es) 1996-07-30
NL300124I1 (nl) 2003-07-01
CA2181377C (en) 2002-05-28
MA23433A1 (fr) 1995-10-01
TNSN95004A1 (fr) 1996-02-06
HUT74943A (en) 1997-03-28
JP3808095B2 (ja) 2006-08-09
EP0740668A1 (en) 1996-11-06
DE10399006I1 (de) 2003-07-31
US6369059B1 (en) 2002-04-09
CZ211696A3 (en) 1997-06-11
BR9506559C8 (pt) 2020-07-07
NZ279199A (en) 1998-01-26
AU7391298A (en) 1998-08-20
US6127542A (en) 2000-10-03
CN1045777C (zh) 1999-10-20
AP556A (en) 1996-11-07
JP2009102386A (ja) 2009-05-14
NO963015D0 (no) 1996-07-19
RO117794B1 (ro) 2002-07-30
NO963015L (no) 1996-09-09
SG49184A1 (en) 1998-05-18
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
SV1995000002A (es) 1995-10-04
WO1995019978A1 (en) 1995-07-27
DE10399006I2 (de) 2004-05-06
EP0740668B1 (en) 1998-07-29
IS1888B (is) 2003-09-01
FI962927A0 (fi) 1996-07-19
JPH09508113A (ja) 1997-08-19
NO2003002I2 (no) 2005-03-21
LU91017I2 (fr) 2003-05-26
JP2004217674A (ja) 2004-08-05
OA10584A (en) 2002-08-26
SK94096A3 (en) 1997-04-09
HU9601982D0 (en) 1996-09-30
AU707055B2 (en) 1999-07-01
HK1013286A1 (en) 1999-08-20
EG25852A (en) 2012-09-10
AU689205B2 (en) 1998-03-26
ZA95424B (en) 1995-09-27
MY114663A (en) 2002-12-31

Similar Documents

Publication Publication Date Title
GB9401090D0 (en) Chemical compounds
CA2340636A1 (en) Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents
AU8816298A (en) Oxindolylquinazoline derivatives as angiogenesis inhibitors
MX9800411A (es) Compuestos quimicos.
GR3006247T3 (en:Method)
CA2445625A1 (en) Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives
DK0505778T3 (da) Derivater af imidazol-2-oner samt fremgangsmåde til fremstilling deraf
TW360650B (en) Pyridin-2-ylmethyloxy-pyridin-5-ylcarbamoyl-indoline derivatives, a process for the preparation thereof, and a pharmaceutical composition comprising them
AU629668B2 (en) Heterocyclic substituted azabicyclic compounds for pharmaceutical use
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
ZA913951B (en) Pyrido(3,4-b)pyrrolo(1,2-e)(1,4,5)oxadiazepines and related analogs,a process for their preparation and their use as medicaments
DE60239324D1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
IT1265256B1 (it) 4-alchil e 4-alchenil delta-3-cefem solfoni
EP0271192A3 (en) Purine histamine h1 antagonists, their preparation and pharmaceutical compositions containing them